Table 1 Patients characteristics
ITT popuration (n = 90) | KRAS wild type | KRAS mutant | ||||
|---|---|---|---|---|---|---|
p53 antibody | p53 antibody | p53 antibody | ||||
Positive | Negative | Positive | Negative | Positive | Negative | |
(n = 36) | (n = 54) | (n = 11) | (n = 31) | (n = 13) | (n = 13) | |
Gender, n (%) | ||||||
Male | 25(69.4) | 30(55.5) | 9(81.8) | 16(51.6) | 9(69.2) | 8(61.5) |
Female | 11(30.5) | 24(44.4) | 2(18.1) | 15(48.3) | 4(30.7) | 5(38.4) |
Age | ||||||
Median (range) | 58.4(39–74) | 60.9(39–75) | 57.3(41–73) | 59.8(39–71) | 59.3(39–74) | 61.3 (41–75) |
<65, n (%) | 26(72.2) | 31(59.2) | 8(72.7) | 19(61.2) | 9(69.2) | 6(46.1) |
≧ 65, n (%) | 10(27.7) | 23(42.5) | 3(27.2) | 12(38.7) | 4(30.7) | 7(53.8) |
ECOG PS at base line, n (%) | ||||||
0 33(91.6) | 51(94.4) | 11(100) | 30(96.7) | 9(69.2) | 12(92.3) | |
1 3(8.3) | 3(5.5) | 0(0) | 1(3.1) | 3(23.0) | 1(7.7) | |
Liver metastasis, n (%) 12(33.3) | 31(57.4) | 7(63.6) | 19(61.2) | 3(23.0) | 5(38.4) | |
Lung metastasis, n (%) 12(33.3) | 22(40.7) | 5(45.4) | 9(29.0) | 4(30.7) | 8(61.5) | |
Lymph node metastasis, n (%) | 21(66.6) | 26(48.1) | 8(72.7) | 17(54.8) | 8(61.5) | 4(30.7) |